Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer. - Yuki S; Kawakami H; Harada K; Kubota Y; Pak K; Kakeji Y; Terashima M; Baba E; Muro K; Sunakawa Y; Ichikawa W; Fujii M (BMC cancer, 2026)